LY 900027
Alternative Names: LY-900027Latest Information Update: 28 Jan 2023
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in Germany (SC, Infusion)
- 12 Aug 2020 Eli Lilly completes the phase I trial in Type-1 diabetes mellitus in Germany (SC) (NCT04161976)
- 26 May 2020 Eli Lilly and Company Limited re-initiates a Phase-I clinical trials in Type 1 diabetes mellitus in Germany (SC) (EudraCT2019-002318-37)